ZYXI - Zynex Inc Stock Price, Fair Value and News

10.74USD-0.20 (-1.83%)Market Closed

Market Summary

USD10.74-0.20

Market Closed

-1.83%

ZYXI Alerts

Big fall in earnings (Y/Y)

ZYXI Stock Price

View Fullscreen

ZYXI RSI Chart

ZYXI Valuation

Market Cap

347.6M

Price/Earnings (Trailing)

42.53

Price/Sales (Trailing)

1.84

EV/EBITDA

30.6

Price/Free Cashflow

20.8

ZYXI Price/Sales (Trailing)

ZYXI Profitability

EBT Margin

5.82%

Return on Equity

24.69%

Return on Assets

6.47%

Free Cashflow Yield

4.81%

ZYXI Fundamentals

ZYXI Revenue

Revenue (TTM)

188.7M

Rev. Growth (Yr)

10.34%

Rev. Growth (Qtr)

-1.59%

ZYXI Earnings

Earnings (TTM)

8.2M

Earnings Growth (Yr)

-99.36%

Earnings Growth (Qtr)

-99.18%

Breaking Down ZYXI Revenue

52 Week Range

6.8810.86

(Low)(High)

Last 7 days

-0.2%

Last 30 days

-11.4%

Last 90 days

-10.2%

Trailing 12 Months

14.7%

How does ZYXI drawdown profile look like?

ZYXI Financial Health

Current Ratio

3.58

Debt/Equity

1.75

Debt/Cashflow

0.31

ZYXI Investor Care

Buy Backs (1Y)

13.31%

Diluted EPS (TTM)

0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	188.7M	0	0	0
2023	169.3M	177.4M	185.8M	184.3M
2022	137.3M	143.0M	149.7M	158.2M
2021	89.0M	100.8M	115.5M	130.3M
2020	51.5M	60.5M	68.7M	80.1M
2019	34.2M	37.0M	40.6M	45.5M
2018	26.9M	29.4M	30.7M	31.9M
2017	13.3M	15.0M	18.2M	23.4M
2016	11.9M	12.1M	13.1M	13.3M
2015	11.1M	12.9M	11.1M	11.6M
2014	17.2M	13.1M	12.3M	11.1M
2013	38.4M	33.9M	29.0M	21.7M
2012	36.5M	38.1M	38.8M	39.7M
2011	26.6M	29.1M	31.6M	34.1M
2010	0	0	0	24.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Zynex Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	lucsok anna	acquired	-	-	1,025	chief operating officer
Apr 30, 2024	moorhead daniel j	acquired	-	-	2,563	chief financial officer
Apr 30, 2024	sandgaard thomas	acquired	-	-	2,563	president, ceo and chairman
Apr 29, 2024	lucsok anna	sold (taxes)	-27,422	11.45	-2,395	chief operating officer
Apr 27, 2024	lucsok anna	acquired	-	-	5,000	chief operating officer
Mar 25, 2024	lucsok anna	sold (taxes)	-97,741	12.74	-7,672	chief operating officer
Mar 25, 2024	sandgaard thomas	sold (taxes)	-28,894	12.74	-2,268	president, ceo and chairman
Mar 25, 2024	moorhead daniel j	sold (taxes)	-77,510	12.74	-6,084	chief financial officer
Mar 05, 2024	moorhead daniel j	acquired	-	-	5,000	chief financial officer
Jan 27, 2024	lucsok anna	acquired	-	-	5,000	chief operating officer

Which funds bought or sold ZYXI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	LSV ASSET MANAGEMENT	added	45.06	530,000	1,348,000	-%
May 06, 2024	Quantbot Technologies LP	new	-	128,376	128,376	0.01%
May 03, 2024	HUNTINGTON NATIONAL BANK	unchanged	-	1.00	12.00	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-1,717,000	-	-%
May 03, 2024	Glassman Wealth Services	sold off	-100	-588	-	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	24.62	588	2,004	-%
May 01, 2024	Janney Montgomery Scott LLC	reduced	-27.01	-232,000	1,121,000	-%
May 01, 2024	HUSSMAN STRATEGIC ADVISORS, INC.	reduced	-16.67	-36,645	649,425	0.15%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	reduced	-13.47	-6,375	366,597	-%

Are Funds Buying or Selling ZYXI?

Are funds buying ZYXI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZYXI

No. of Funds

ZYXI Alerts

Big fall in earnings (Y/Y)

Unveiling Zynex Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 06, 2023	blackrock inc.	4.1%	1,477,842	SC 13G/A
May 24, 2023	sandgaard thomas	44.6%	16,331,423	SC 13D/A
Feb 01, 2023	blackrock inc.	9.1%	3,396,632	SC 13G/A
Feb 07, 2022	blackrock inc.	8.7%	3,035,364	SC 13G/A
Feb 02, 2021	blackrock inc.	8.3%	2,900,347	SC 13G
Dec 02, 2020	sandgaard thomas	43.66%	15,281,821	SC 13D/A
Jul 20, 2020	sandgaard thomas	36.5%	15,256,642	SC 13D/A
Mar 04, 2020	sandgaard thomas	42.84%	16,631,392	SC 13D/A

Recent SEC filings of Zynex Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
Apr 30, 2024	8-K	Current Report
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	10-Q	Quarterly Report
Apr 12, 2024	DEFA14A	DEFA14A
Apr 01, 2024	DEF 14A	DEF 14A
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 26, 2024	4	Insider Trading

Peers (Alternatives to Zynex Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.71	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.76	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.87	0.4	7.94%	-1661.78%
ANIK	420.5M	166.7M	10.85%	9.31%	-5.09	2.52	6.67%	-456.34%
ANGO	245.9M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

Zynex Inc News

Latest updates

Zynex Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.6%	47.00	47.00	50.00	45.00	42.00	49.00	42.00	37.00	31.00	40.00	35.00	31.00	24.00	26.00	20.00	19.00	15.00	14.00	12.00	10.00	9.00
Costs and Expenses	2.3%	46.00	45.00	44.00	42.00	42.00	39.00	35.00	32.00	29.00	29.00	27.00	27.00	25.00	23.00	19.00	15.00	13.00	10.00	9.00	8.00	7.00
S&GA Expenses	7.9%	23.00	22.00	22.00	22.00	21.00	19.00	17.00	16.00	14.00	14.00	13.00	14.00	14.00	12.00	9.00	7.00	6.00	5.00	4.00	3.00	2.00
EBITDA Margin	-16.2%	0.06*	0.08*	0.12*	0.13*	0.14*	0.15*	0.17*	0.19*	0.20*	0.19*	0.13*	0.08*	-	-	-	-	-	-	-	-	-
Interest Expenses	-39.9%	-0.51	-0.37	-0.33	-0.32	-0.08	-0.09	-0.11	-0.11	-0.12	-0.02	-0.02	-0.04	-0.01	0.00	0.00	0.00	0.00	-0.01	0.00	-	-
Income Taxes	-99.8%	0.00	1.00	1.00	1.00	0.00	2.00	2.00	1.00	1.00	3.00	2.00	1.00	-0.38	0.00	0.00	1.00	-0.50	1.00	0.00	0.00	1.00
Earnings Before Taxes	-99.3%	0.00	2.00	5.00	4.00	2.00	10.00	6.00	4.00	2.00	12.00	8.00	4.00	-1.09	2.00	1.00	4.00	2.00	4.00	2.00	3.00	3.00
EBT Margin	-14.7%	0.06*	0.07*	0.11*	0.12*	0.13*	0.14*	0.16*	0.18*	0.18*	0.17*	0.11*	0.06*	-	-	-	-	-	-	-	-	-
Net Income	-99.2%	0.00	1.00	4.00	3.00	2.00	7.00	5.00	3.00	1.00	9.00	6.00	3.00	-0.71	2.00	1.00	3.00	3.00	3.00	2.00	2.00	2.00
Net Income Margin	-18.0%	0.04*	0.05*	0.09*	0.10*	0.10*	0.11*	0.12*	0.14*	0.14*	0.13*	0.09*	0.05*	-	-	-	-	-	-	-	-	-
Free Cashflow	-65.9%	2.00	6.00	9.00	1.00	2.00	5.00	7.00	-0.32	2.00	7.00	4.00	1.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.8%	126	137	151	153	111	116	115	120	132	133	91.00	84.00	70.00	72.00	65.00	37.00	33.00	28.00	25.00	22.00	19.00
Current Assets	-11.2%	78.00	88.00	103	108	65.00	70.00	67.00	71.00	82.00	83.00	70.00	62.00	61.00	63.00	58.00	30.00	26.00	23.00	19.00	16.00	14.00
Cash Equivalents	-26.3%	33.00	45.00	43.00	59.00	17.00	20.00	24.00	27.00	39.00	43.00	35.00	32.00	33.00	39.00	41.00	17.00	15.00	14.00	12.00	10.00	9.00
Inventory	18.1%	15.00	13.00	14.00	14.00	14.00	13.00	14.00	15.00	13.00	11.00	9.00	10.00	11.00	9.00	6.00	5.00	3.00	2.00	2.00	1.00	2.00
Net PPE	3.9%	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.6%	93.00	91.00	93.00	90.00	47.00	50.00	50.00	51.00	56.00	59.00	27.00	26.00	14.00	15.00	11.00	10.00	10.00	9.00	8.00	8.00	7.00
Current Liabilities	17.4%	22.00	19.00	20.00	14.00	21.00	21.00	20.00	19.00	22.00	23.00	10.00	9.00	9.00	10.00	7.00	6.00	6.00	5.00	5.00	4.00	4.00
Short Term Borrowings	-	-	-	-	-	5.00	5.00	5.00	5.00	-	5.00	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	0.4%	58.00	58.00	57.00	57.00	4.00	-	7.00	8.00	9.00	11.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.4%	58.00	58.00	57.00	57.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-28.2%	33.00	46.00	59.00	62.00	64.00	66.00	65.00	69.00	76.00	74.00	63.00	57.00	56.00	57.00	54.00	27.00	23.00	20.00	16.00	14.00	12.00
Retained Earnings	0.0%	27.00	27.00	26.00	22.00	19.00	17.00	10.00	5.00	1.00	-	32.00	26.00	23.00	23.00	22.00	20.00	17.00	14.00	11.00	9.00	7.00
Additional Paid-In Capital	0.4%	91.00	91.00	91.00	83.00	82.00	82.00	82.00	81.00	81.00	80.00	38.00	38.00	37.00	37.00	36.00	11.00	10.00	9.00	9.00	9.00	8.00
Shares Outstanding	-3.2%	32.00	33.00	34.00	36.00	37.00	37.00	38.00	39.00	40.00	40.00	38.00	38.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.09	-0.09	-0.09	-0.09	-0.09	-0.09	-0.09
Float	-	-	-	-	205	-	-	-	175	-	-	-	308	-	-	-	422	-	-	-	292	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-66.6%	2,068	6,188	8,893	741	1,934	4,757	7,411	-176	1,754	7,538	3,689	1,027	-5,305	-1,696	-769	2,651	632	2,098	1,841	600	1,764
Share Based Compensation	8.7%	734	675	654	660	307	640	578	535	589	588	533	401	108	875	730	579	497	264	258	158	140
Cashflow From Investing	-101.6%	-153	9,424	-10,006	-210	-174	-86.00	-120	-140	-72.00	-16,186	-66.00	-55.00	-299	-226	-105	-357	-297	-28.00	9.00	-95.00	-46.00
Cashflow From Financing	-0.6%	-13,633	-13,550	-15,119	41,426	-5,112	-8,059	-10,636	-12,054	-5,047	15,892	-585	-2,081	-130	-134	25,187	37.00	210	36.00	30.00	130	-2,427
Dividend Payments	50.0%	3.00	2.00	-	-	-	-	-	-	3,613	1.00	-	-	-	-	-	-	-	-	3.00	-	2,259
Buy Backs	38.3%	13,280	9,600	14,934	6,115	3,353	6,600	9,156	10,655	-	-1,039	547	2,045	75.00	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ZYXI Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
NET REVENUE
Total net revenue	$ 46,531,000	$ 42,170,000
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies	9,298,000	9,269,000
Sales and marketing	23,380,000	21,227,000
General and administrative	13,328,000	11,390,000
Total costs of revenue and operating expenses	46,006,000	41,886,000
Income from operations	525,000	284,000
Other income (expense)
Gain on sale of fixed assets		2,000
Gain on change in fair value of contingent consideration		1,400,000
Interest expense, net	(512,000)	(84,000)
Other income (expense), net	(512,000)	1,318,000
Income from operations before income taxes	13,000	1,602,000
Income tax expense	3,000	33,000
Net income	$ 10,000	$ 1,569,000
Net income per share:
Basic (in dollars per share)	$ 0.00	$ 0.04
Diluted (in dollars per share)	$ 0.00	$ 0.04
Weighted average basic shares outstanding (in shares)	32,344	36,694
Weighted average diluted shares outstanding (in shares)	32,827	37,442
Devices
NET REVENUE
Total net revenue	$ 14,025,000	$ 11,944,000
Supplies
NET REVENUE
Total net revenue	$ 32,506,000	$ 30,226,000

ZYXI Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,861	$ 44,579
Accounts receivable, net	25,439	26,838
Inventory, net	15,476	13,106
Prepaid expenses and other	4,213	3,332
Total current assets	77,989	87,855
Property and equipment, net	3,234	3,114
Operating lease asset	11,857	12,515
Finance lease asset	537	587
Deposits	409	409
Intangible assets, net of accumulated amortization	7,932	8,158
Goodwill	20,401	20,401
Deferred income taxes	3,866	3,865
Total assets	126,225	136,904
Current liabilities:
Accounts payable and accrued expenses	10,325	8,433
Operating lease liability	3,881	3,729
Finance lease liability	183	196
Income taxes payable	637	633
Accrued payroll and related taxes	6,729	5,541
Total current liabilities	21,755	18,532
Long-term liabilities:
Convertible senior notes, less issuance costs	57,839	57,605
Operating lease liability	13,184	14,181
Finance lease liability	347	457
Total liabilities	93,125	90,775
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 100,000,000 shares authorized; 42,048,385 issued and 31,879,892 outstanding as of March 31, 2024. 41,980,166 issued and 32,933,776 outstanding as of December 31, 2023.	32	33
Additional paid-in capital	91,259	90,878
Treasury stock of 9,666,879 and 8,545,044 shares at March 31, 2024 and December 31, 2023, respectively, at cost	(84,981)	(71,562)
Retained earnings	26,790	26,780
Total stockholders' equity	33,100	46,129
Total liabilities and stockholders' equity	$ 126,225	$ 136,904

About Zynex Inc

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

CEO	Mr. Thomas Sandgaard
WEBSITE	zynex.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	900

Zynex Inc Frequently Asked Questions

What is the ticker symbol for Zynex Inc? What does ZYXI stand for in stocks?

ZYXI is the stock ticker symbol of Zynex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zynex Inc (ZYXI)?

As of Tue May 07 2024, market cap of Zynex Inc is 347.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZYXI stock?

You can check ZYXI's fair value in chart for subscribers.

What is the fair value of ZYXI stock?

You can check ZYXI's fair value in chart for subscribers. The fair value of Zynex Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zynex Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZYXI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zynex Inc a good stock to buy?

The fair value guage provides a quick view whether ZYXI is over valued or under valued. Whether Zynex Inc is cheap or expensive depends on the assumptions which impact Zynex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZYXI.

What is Zynex Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, ZYXI's PE ratio (Price to Earnings) is 42.53 and Price to Sales (PS) ratio is 1.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZYXI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Zynex Inc's stock?

In the past 10 years, Zynex Inc has provided 0.438 (multiply by 100 for percentage) rate of return.